Osteogenic Protein-1 Overcomes the Inhibitory Effect of Nicotine on Posterolateral Lumbar Fusion
Patel T, Erulkar J, Grauer J, Troiano N, Panjabi M, Friedlaender G. Osteogenic Protein-1 Overcomes the Inhibitory Effect of Nicotine on Posterolateral Lumbar Fusion. Spine 2001, 26: 1656-1661. PMID: 11474350, DOI: 10.1097/00007632-200108010-00004.Peer-Reviewed Original ResearchConceptsPosterolateral lumbar fusionOsteogenic protein-1Inhibitory effectProtein 1Lumbar fusionRabbit posterolateral lumbar fusion modelRabbit posterolateral spine fusion modelFusion massRabbit modelSubcutaneous mini-osmotic pumpsPosterolateral lumbar fusion modelMini-osmotic pumpsNew Zealand white rabbitsNew Zealand white rabbit modelZealand white rabbitsPosterolateral spine fusionSpine fusion modelPosterolateral intertransverse process fusionWhite rabbit modelPresence of nicotineIntertransverse process fusionBone graft alternativesBony fusionBACKGROUND DATASpine fusionOsteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions.
Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. Journal Of Bone And Joint Surgery 2001, 83-A Suppl 1: s151-8. PMID: 11314793, PMCID: PMC1425155, DOI: 10.2106/00004623-200100002-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdultBone Morphogenetic Protein 7Bone Morphogenetic ProteinsBone TransplantationCollagenDrug CarriersDrug Delivery SystemsFemaleFracture Fixation, IntramedullaryFracture HealingFractures, UnunitedHumansMaleProspective StudiesRadiographyRecombinant ProteinsTibial FracturesTransforming Growth Factor betaConceptsTibial nonunionAdverse eventsRadiographic resultsClinical trialsOsteogenic protein-1Bone autograftAutogenous boneChronic donor site painAutograft-treated patientsFresh autogenous bonePlain radiographic evaluationMulti-center clinical trialPercent of patientsSeverity of painDonor site painGroup of patientsProtein 1Bone morphogenetic proteinNumerous animal modelsInvestigational device exemptionDonor site morbiditySame time pointsType ISite painClinical course